GlycoMimetics Inc (GLYC)
0.3168
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 16:00
0.3133
0.00 (0.00%)
After-Hours: 20:00
GlycoMimetics Free Cash Flow: -35.02M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -35.02M |
| June 30, 2024 | -35.72M |
| March 31, 2024 | -33.81M |
| December 31, 2023 | -34.90M |
| September 30, 2023 | -35.20M |
| June 30, 2023 | -35.13M |
| March 31, 2023 | -44.41M |
| December 31, 2022 | -46.54M |
| September 30, 2022 | -51.44M |
| June 30, 2022 | -59.77M |
| March 31, 2022 | -57.11M |
| December 31, 2021 | -57.50M |
| September 30, 2021 | -54.42M |
| June 30, 2021 | -48.99M |
| March 31, 2021 | -49.93M |
| December 31, 2020 | -39.31M |
| September 30, 2020 | -42.39M |
| June 30, 2020 | -44.34M |
| March 31, 2020 | -41.25M |
| December 31, 2019 | -52.13M |
| September 30, 2019 | -49.36M |
| June 30, 2019 | -46.00M |
| Date | Value |
|---|---|
| March 31, 2019 | -47.62M |
| December 31, 2018 | -43.46M |
| September 30, 2018 | -41.82M |
| June 30, 2018 | -37.97M |
| March 31, 2018 | -31.16M |
| December 31, 2017 | -30.06M |
| September 30, 2017 | -28.05M |
| June 30, 2017 | -29.49M |
| March 31, 2017 | -30.31M |
| December 31, 2016 | -30.44M |
| September 30, 2016 | -31.00M |
| June 30, 2016 | -9.800M |
| March 31, 2016 | -9.05M |
| December 31, 2015 | -8.510M |
| September 30, 2015 | -7.719M |
| June 30, 2015 | -26.08M |
| March 31, 2015 | -10.60M |
| December 31, 2014 | -4.494M |
| September 30, 2014 | -3.903M |
| June 30, 2014 | -2.476M |
| March 31, 2014 | -14.34M |
| December 31, 2013 | -15.62M |
Free Cash Flow Range, Past 5 Years
-59.77M
Minimum
Jun 2022
-33.81M
Maximum
Mar 2024
-44.97M
Average
-44.38M
Median
Free Cash Flow Benchmarks
| Biomarin Pharmaceutical Inc | 300.88M |
| Arbutus Biopharma Corp | -71.92M |
| Revance Therapeutics Inc | -194.91M |
| FibroGen Inc | -126.23M |
| Cidara Therapeutics Inc | -160.15M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -7.994M |
| Free Cash Flow Per Share (Quarterly) | -0.124 |
| Free Cash Flow Yield | -171.5% |